<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935647</url>
  </required_header>
  <id_info>
    <org_study_id>00090838</org_study_id>
    <nct_id>NCT02935647</nct_id>
  </id_info>
  <brief_title>Burst Suppression Anesthesia for Treatment of Severe Depression</brief_title>
  <official_title>Burst Suppression Anesthesia for Treatment of Severe Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if the antidepressant effects of deep anesthesia via&#xD;
      propofol are related to EEG burst suppression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten individuals with treatment resistant major depressive disorder will undergo 10 treatments&#xD;
      of deep anesthesia via propofol over a 3-week period. Depression will be evaluated before and&#xD;
      after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diprivan</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Propofol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Diagnosis of Major Depressive Disorder (MDD) or bipolar Disorder (I or II, most&#xD;
             recent episode must be depression&#xD;
&#xD;
               -  Failed at least 2 anti-depressant treatments and no ECT in past 6 months&#xD;
&#xD;
               -  Age between 18-55 years&#xD;
&#xD;
               -  BMI &lt; 35&#xD;
&#xD;
               -  Hamilton Rating Scale for Depression (HSRD) score &gt; 18&#xD;
&#xD;
               -  Quick Inventory of Depression Scale (QIDS) score &gt; 10.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Diagnosis of primary psychotic disorder, dysthymia, or personality disorder&#xD;
&#xD;
               -  Significant pre-morbid cognitive impairment&#xD;
&#xD;
               -  Hypertension and current use of ACE inhibitor or AR blocker medications&#xD;
&#xD;
               -  Symptomatic coronary artery disease or congestive heart failure&#xD;
&#xD;
               -  History of transient ischemic or neurologic signs during the past year&#xD;
&#xD;
               -  History of or susceptibility to malignant hyperthermia&#xD;
&#xD;
               -  Contraindication to isoflurane or propofol anesthesia (as determined by&#xD;
                  anesthesiologist)&#xD;
&#xD;
               -  Diabetes requiring insulin&#xD;
&#xD;
               -  Poor kidney function&#xD;
&#xD;
               -  Chronic use of benzodiazepines or opioids&#xD;
&#xD;
               -  Individuals incompetent to provide consent (e.g. catatonic, psychotic).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Neuropsychiatric Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Brian Mickey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02935647/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

